Key Drivers of the HIMS Stock Move
- HIMS stock fell on October 17 following President Trump’s comments that “fat-loss drugs will be a lot lower in price,” threatening the company’s weight-loss drug business model.
- The stock had just rallied on October 15 after announcing a new menopause and perimenopause specialty platform, demonstrating strong fundamental expansion beyond weight-loss offerings.
- Unusual options activity surged with over $20 million in premium paid on October 16-17, showing heavy put buying as traders positioned for further downside following the political headline risk.
The telehealth platform had been trading near multi-year highs at $62.82 on October 15, up 150% year-to-date, before Trump’s remarks sent shares tumbling. This volatility comes as HIMS attempts to diversify revenue streams while competing with major pharmaceutical companies like Eli Lilly and Novo Nordisk in the lucrative GLP-1 weight-loss market. The company reported strong Q2 2025 earnings on August 4 with revenue of $544.8 million (up 72.6% year-over-year), though EPS of $0.17 missed estimates by 19%.
HIMS Insider Selling Explodes
Executive selling activity has been consistent throughout August-October 2025, with CEO Andrew Dudum disposing of $50.7 million in shares across multiple transactions. CFO Oluyemi Okupe sold $15.1 million worth of stock, while other C-suite executives also reduced positions. This selling appears scheduled rather than reactive, as transactions occurred regularly before the recent political developments. However, the magnitude of insider sales (exceeding $60 million total) during a period of elevated stock prices suggests executives were taking profits at favorable levels.
HIMS Unusual Options
Heavy options activity dominated October 16-17, with over 200 significant transactions totaling approximately $20 million in premium. Notable activity included aggressive put buying: the January 2026 $29 puts saw $560K in premium, while October 24 $75 puts accumulated $370K. Call buying also appeared, particularly on longer-dated contracts like the December 2027 $100 calls ($505K premium), suggesting some traders expect recovery. The mix of protective puts and speculative calls reflects deep uncertainty about regulatory risk versus growth potential.
HIMS Seasonality
Based on data since October 2020 (6 samples for October), HIMS historically shows weak seasonal performance in October, with only 33% positive periods and an average decline of 7.2%. The current October decline aligns with this pattern. November has been the strongest month historically (80% positive, +28.9% average), potentially offering hope for recovery. However, August has been consistently weak (20% positive, -17.9% average), which preceded the recent volatility.
HIMS Relative Performance
HIMS relative strength versus the SPX collapsed dramatically in August, falling from the 99.8th percentile on July 31 to just 1.4th percentile by August 21. The stock recovered spectacularly in late September, reaching the 94.4th percentile on September 23, before retreating to the 90.4th percentile following Trump’s comments. This roller coaster demonstrates extreme sensitivity to sentiment shifts around the company’s weight-loss drug positioning.
Analyst Focus
Analyst coverage remains cautious following the summer selloff. Truist Securities downgraded their price target from $48 to $37 on August 18 while maintaining a hold rating. Canaccord Genuity remains the most bullish with a buy rating and $68 target (September 12). Needham continues to rate the stock as hold. The median analyst price target of approximately $48-68 suggests limited upside from current levels near $50, reflecting uncertainty about regulatory pressures on pricing.
How to Track HIMS Live With TrendSpider
Monitor HIMS volatility and key technical levels as political and regulatory developments unfold:
- Track insider trades for signs executives are accelerating or pausing their selling programs.
- Monitor unusual options flow for shifts in sentiment as traders position for earnings or regulatory news.
- Watch relative performance versus healthcare peers to gauge sector-specific versus company-specific pressures.
Market Update Into September 14th: Rate Hike Incoming?